Profound Medical has success at Mount Sinai Hospital

Executive Summary

• Mount Sinai Hospital has become the first facility in the Metro New York area to successfully deliver an incision-free, MRI-guided prostate treatment using the Tulsa-PRO system.
• The procedure was performed by a collaborative team from Mount Sinai’s Department of Urology and Department of Diagnostic, Molecular and Interventional Radiology, marking a significant clinical milestone for the health system.
• Profound Medical Corp. highlights this adoption as evidence of the Tulsa-PRO system's capability to treat a wide range of prostate diseases while preserving patient function, with the patient discharged the same day.

Key Details

• First-in-Region Milestone: Mount Sinai is the first health system in the New York Metro area to offer the Tulsa-PRO procedure.
• Procedure Details: The Tulsa-PRO system uses robotically controlled directional ultrasound delivered from inside the urethra to heat prostate tissue to 55°C–57°C ("kill temperature").
• Technology Features:
  • Real-time MRI thermography allows for continuous visualization and autonomous temperature adjustment.
  • The system is AI-driven and incision-free.
  • Designed to protect surrounding nerves and anatomy, minimizing side effects like urinary incontinence and erectile dysfunction.
• Clinical Outcome: The first patient was treated successfully, experienced no procedural blood loss, had no overnight hospital stay, and was discharged the same day.
• Key Personnel Involved:
  • Michael Palese, MD (Chair, Department of Urology, Mount Sinai Downtown)
  • Neil Rofsky, MD, MHA (Chair, Diagnostic, Molecular and Interventional Radiology, Mount Sinai Health System)
  • Kyrollis Attalla, MD (Assistant Professor, Department of Urology)
  • Christine Chen, MD (Associate Professor, Diagnostic, Molecular and Interventional Radiology)

Notable Quotes

• Arun Menawat, CEO and Chairman, Profound Medical Corp.: "With this milestone, Mount Sinai continues to establish itself as a leader in robotic surgical care, becoming the first health system in the New York Metro area to offer the innovative, AI-driven, MRI-guided and incision-free Tulsa procedure to prostate disease patients."
• Arun Menawat, CEO and Chairman, Profound Medical Corp.: "What makes the Tulsa procedure unique is its ability to treat an unrivaled range of prostate diseases, severities and aggressions, while preserving crucial functions like continence and sexual health. We are excited to welcome Mount Sinai as a valued Tulsa-PRO site."
• Ash Tewari, MD, MBBS, MCh, Surgeon-in-Chief, Tisch Cancer Hospital: "This unique collaboration between the department of urology and the department of interventional radiology at Mount Sinai will pave the way for future studies and guidelines in prostate cancer and BPH using Tulsa-PRO. Patients will have another option for best-in-class treatment of these complex conditions."